BTK and carcinoma of esophagus: Furthermore, BTK-inhibition with ibrutinib, an irreversible selective inhibitor of BTK, has been shown to directly inhibit growth of c-MYC and/or HER-2 amplified oesophageal cancer cell lines with downregulation of c-MYC and p-ERK, as well as corresponding cell-cycle arrest [15].